Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978859 | 0.79 | GPR119 (0.37) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL19978789 | 0.79 | GPR119 (0.37) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL22032711 | 0.79 | NAMPT (0.39) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL20647832 | 0.76 | NR1H2 (0.51) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL16903485 | 0.76 | NR1H2 (0.51) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL16903487 | 0.76 | NR1H2 (0.51) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL20647830 | 0.76 | NR1H2 (0.51) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL1257642 | 0.73 | USP2 (0.43) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL19230405 | 0.73 | NR1H2 (0.42) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL17081077 | 0.72 | NR1H2 (0.44) | NR1H2GPR119NAMPTUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380309-A1 | CHOLINE METABOLISM INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-01 | — | — | US | disclosed |
| WO-2020117942-A1 | CHOLINE METABOLISM INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117942-A1 | CHOLINE METABOLISM INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380309-A1 | CHOLINE METABOLISM INHIBITORS | CHKB, CRAT, HNMT | NR1H2 360/4885GPR119 82/4885NAMPT 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.